Charles River Laboratories Intl. Inc vs Ford Motor Company — how do they compare? Charles River Laboratories Intl. Inc trades at $303.44 (market cap $14.23B), while Ford Motor Company trades at $12.17 (market cap $48.85B). The key difference: Ford Motor Company is far larger — about 3.4× Charles River Laboratories Intl. Inc's market cap, and Ford Motor Company pays a 4.9% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Ford Motor Company for 105 Days on average.
| CRL | F | |
|---|---|---|
Market Cap | $14.23B | $48.85B |
Volume | 1,176,885 | 57,748,965 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $17.44 |
52-Week Low | $149.93 | $11.21 |
Typical Hold Time | 33 Days | 105 Days |
Enterprise Value | $17.06B | $180.81B |
Dividend Yield | — | 4.9% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Ford Motor Company (F) trades at $12.23, up 0.87% with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and high debt levels. Recent news highlights a 6.6% Q3 sales decline and supplier disruptions affecting F-150 production, though the company maintains its No. 3 U.S. sales position.
The outlook remains challenging with persistent losses and competitive pressures, though analyst consensus suggests 30% upside to the $15.90 price target. Key risks include ongoing operational issues, high leverage, and market share erosion to Asian rivals. Investment appeal hinges on execution improvements and hybrid vehicle transition success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →